Steroid hormones, including progestagens, estrogens, androgens, corticosteroids, and their precursor cholesterol, perform essential functions in the successful establishment and maintenance of pregnancy and normal fetal development. As the core endocrine organ at the prenatal stage, the human placenta is involved in the biosynthesis, metabolism, and delivery of steroid hormones. Steroidogenic pathways are tightly regulated by placenta-intrinsic cytochrome P450 and hydroxysteroid dehydrogenase. However, the relationship between placental steroidogenic enzyme expression and adverse pregnancy outcomes is controversial. In this review, we summarize the possible upstream regulatory mechanisms of placental steroidogenic enzymes in physiologic and pathophysiologic states. We also describe the human placental barrier model and examine the potential of single-cell sequencing for evaluating the primary functions and cellular origin of steroidogenic enzymes. Finally, we examine the existing evidence for the association between placental steroidogenic enzyme dysregulation and adverse pregnancy outcomes.
In 2019, preterm births (PTB) accounted for approximately 0.66 million deaths globally. PTB is also associated with a significantly higher risk of mortality and long-term complications for newborns. Long-term studies associated several factors, including disruption of immune tolerance and inflammation, with PTB. However, the pathogenesis of PTB remains unclear. Gonadal steroid hormones are critical for pregnancy maintenance and regulation of immune and inflammatory responses. However, it is not clear how unbalanced gonadal steroid hormones, such as imbalanced estrogen/androgen or estrogen/progesterone contribute to PTB. In this review, we discuss how gonadal steroid hormones mediate dysfunction in immune tolerance and inflammatory responses, which are known to promote the occurrence of PTB, and provide insight into PTB prediction.
Objective: To systematically analyze the genetic features of fetal renal abnormalities and the prenatal characteristics of 17q12 microdeletion syndrome. Methods: We retrospective analysis of fetal diagnosed with renal abnormalities from January 2016 to August 2022. Chromosome test, fetal renal abnormalities and pregnancy outcomes were performed in a descriptive analysis. Results: 141 patients (4.5%) showed abnormal renal development and 26 patients (26/141) with hyperechogenic kidneys (HCK), 14 (14/26) cases showed chromosomal abnormalities, 12 patients were 17q12 microdeletion syndrome. In addition, there were 14 17q12 microdeletion syndrome among the patients, and 12 fetal had hyperechogenic kidneys (HCK), 7 fetal were verified by couples, 5 fetal had new mutations, and 2 fetal inherited from parents. After excluding patients with HCK, the polycystic kidney has a higher rate of chromosomal abnormalities compared to polycystic renal dysplasia and renal dysplasia. The chromosomal of isolated horseshoe kidney, hydronephrosis, ectopic kidney and unilateral kidney often were normal, and the chromosomal abnormalities rate was increased when combined with other abnormalities. Conclusion: Fatal HCK was closely related to 17q12 microdeletion syndrome. The chromosome test result of patients with isolated polycystic kidney dysplasia, kidney dysplasia, horseshoe kidney, hydronephrosis, kidney deficiency, and ectopic kidney were mostly normal. Prenatal diagnosis was recommended, specifically in the fetus had non-isolated renal abnormalities. Most patients with normal chromosomes or uncertain clinical significance choose to produce, but adverse pregnancy outcomes were not excluded. This study will provide more data support for fetal renal abnormalities.